Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 2/20 | 0.80 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | MTHFD1 | P11586 | 3/20 | 0.58 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.57 |
| ▸ | MTHFD2 | P13995 | 3/20 | 0.51 |
| ▸ | FPGS | Q05932 | 2/20 | 0.51 |
| ▸ | ATIC | P31939 | 2/20 | 0.51 |
| ▸ | TYMS | P04818 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leucovorin SCHEMBL5132046 | 1.00 | DHFR (0.80) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| Folinic Acid SCHEMBL29369091 | 1.00 | DHFR (0.80) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| Leucovorin SCHEMBL21632556 | 1.00 | DHFR (0.80) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| Leucovorin SCHEMBL4708750 | 1.00 | DHFR (0.80) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| Leucovorin SCHEMBL8349 | 1.00 | DHFR (0.80) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| Leucovorin SCHEMBL8350 | 1.00 | DHFR (0.80) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| Leucovorin SCHEMBL571902 | 1.00 | DHFR (0.80) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| Leucovorin SCHEMBL9054117 | 0.99 | DHFR (0.78) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| Leucovorin SCHEMBL16207660 | 0.99 | DHFR (0.78) | DHFRLMNAMTHFD1SOSTMTHFD2 | |
| Leucovorin SCHEMBL9054183 | 0.99 | DHFR (0.78) | DHFRLMNAMTHFD1SOSTMTHFD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 377 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124144-A1 | COMPOSITIONS COMPRISING DISODIUM LEVOFOLINATE | Acrotech Biopharma Inc. (US) | 2026-05-07 | — | — | US | claimed |
| US-12564556-B1 | Compositions comprising disodium levofolinate | Acrotech Biopharma Inc. (US) | 2026-03-03 | — | — | US | claimed |
| US-12539276-B1 | Compositions comprising disodium levofolinate | Acrotech Biopharma Inc. (US) | 2026-02-03 | — | — | US | claimed |
| US-20250215039-A1 | NUCLEOSIDES FOR TREATING CANCER | PRIMEFOUR THERAPEUTICS INC (US) | 2025-07-03 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| WO-2025101623-A1 | METHODS OF TREATING CANCER | AMGEN INC. (US) | 2025-05-15 | — | — | WO | claimed |
| WO-2025100428-A1 | COMBINATION OF ANTI-CD147 ANTIBODY AND ANOTHER ANTITUMOR AGENT | 第一三共株式会社 | 2025-05-15 | — | — | WO | claimed |
| US-20250127782-A1 | METHODS OF TREATING CANCER | AMGEN INC. | 2025-04-24 | — | — | US | claimed |
| EP-3893913-B1 | TRANSFERRIN RECEPTOR TARGETING PEPTIDES | FRED HUTCHINSON CANCER CENTER (US) | 2025-03-26 | — | — | EP | claimed |
| CN-119548521-A | Anti-aging composition for middle-aged and elderly people | 深圳奥萨制药有限公司 | 2025-03-04 | — | — | CN | claimed |
| CN-112691107-B | Pharmaceutical composition and application thereof | 北京斯利安药业有限公司 | 2022-09-02 | — | — | CN | claimed |
| US-20220211657-A1 | METHODS OF TREATING GASTROINTESTINAL CANCERS AND TUMORS THEREOF USING COMBINATION THERAPY | GEORGETOWN UNIVERSITY | 2022-07-07 | — | — | US | claimed |
| EP-3099816-B1 | ADMINISTRATION REGIME | ISOFOL MEDICAL AB (SE) | 2022-07-06 | — | — | EP | claimed |
| CN-113336757-B | Preparation method of levofolinic acid crystal | 南京海纳医药科技股份有限公司 | 2022-05-13 | — | — | CN | claimed |
| WO-2022087018-A1 | IMPROVED FLUOROURACIL-BASED MULTI-AGENT CHEMOTHERAPY FOR TREATMENT OF METASTATIC COLORECTAL CANCER | G1 THERAPEUTICS, INC. (US) | 2022-04-28 | — | — | WO | claimed |
| CN-114324618-A | Method for separating and detecting calcium levofolinate intermediate and related substances | 重庆华邦制药有限公司 | 2022-04-12 | — | — | CN | claimed |
| CN-114280167-A | Method for separating and detecting bis (2-hydroxyethyl) disulfide in calcium levofolinate | 重庆华邦制药有限公司 | 2022-04-05 | — | — | CN | claimed |
| WO-2022066882-A1 | METHOD FOR TREATING CANCER WITH A REVERSE TRANSCRIPTASE INHIBITOR | ONCOLINEA PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | claimed |
| WO-2022058970-A1 | KOJIC ACID DERIVATIVE AS SELECTIVE INHIBITOR OF MITOSIS IN COLORECTAL AND GLIOBLASTOMA CANCER CELLS | UNIVERSITÀ DEGLI STUDI DI CAGLIARI (IT) | 2022-03-24 | — | — | WO | claimed |
| US-20220024940-A1 | STABLE SALT OF 5,10-METHYLENE-(6R)-TETRAHYDROFOLIC ACID | Merck & Cie (CH) | 2022-01-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12564556-B1 | Compositions comprising disodium levofolinate | FOLR1, FOLR2, SLC19A1 | DHFR 7/4885LMNA 2042/4885MTHFD1 8/4885 |
| US-20250127782-A1 | METHODS OF TREATING CANCER | KRAS, NRAS, EGFR | DHFR 9/4885LMNA 3937/4885MTHFD1 29/4885 |
| US-20260124144-A1 | COMPOSITIONS COMPRISING DISODIUM LEVOFOLINATE | SLC19A1, FOLR1, FOLR2 | DHFR 8/4885LMNA 1884/4885MTHFD1 4/4885 |
| US-12539276-B1 | Compositions comprising disodium levofolinate | SLC19A1, FOLR2, FOLR1 | DHFR 8/4885LMNA 2673/4885MTHFD1 7/4885 |
| US-20250215039-A1 | NUCLEOSIDES FOR TREATING CANCER | UNG, OGG1, NTPCR | DHFR 152/4885LMNA 1053/4885MTHFD1 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.